Advanced CRISPR-Cas Genome Engineering Coupled with Nanotechnology-Based Drug Delivery for Treating Genetic and Infectious Diseases
Background CRISPR-Cas genome editing offers curative potential for monogenic disorders and persistent infections, but its clinical translation is hindered by delivery inefficiency, off-target effects, and immunogenicity. Nanocarrier platforms address these barriers by enabling targeted, transient intracellular delivery...